Cenix Inks RNAi-Based Target Identification, Validation Deal with Bayer

Cenix BioScience said this week that it has signed a deal to use its genome-wide siRNA library to help Bayer HealthCare screen all known human druggable genes in an effort to identify and validate new drug targets.

Cenix said that, using cell-based assays developed in partnership with Bayer researchers, it expects to screen more than 6,000 genes in less than nine months.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Technology Review reports that researchers in the US have used CRISPR to modify a number of human embryos.

By introducing genes from butterfly peas and Canterbury bells, researchers in Japan have developed a blue chrysanthemum, according to NPR.

Plant researchers plan to sequence some 10,000 samples that represent the major plant clades, ScienceInsider reports.

In Nature this week: a Danish reference genome, and more.